Activating NFE2L2 mutations and inactivating KEAP1 mutations were demonstrated to play important roles in tumor progression by preventing the degradation of nuclear factor E2-related factor2 (Nrf2), and the Nrf2/Keap1 pathway recently attracted attention as a potential therapeutic target for HCC [3,7,8]. This evidence concerns the gene KEAP1 and neoplasm.